![Kenneth W. Narducy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kenneth W. Narducy
President chez St. Charles Pharmaceuticals
Postes actifs de Kenneth W. Narducy
Sociétés | Poste | Début | Fin |
---|---|---|---|
St. Charles Pharmaceuticals | President | 17/09/2009 | - |
NeuroNascent, Inc.
![]() NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | Directeur/Membre du Conseil | 12/04/2017 | - |
Directeur des opérations | - | - |
Historique de carrière de Kenneth W. Narducy
Anciens postes connus de Kenneth W. Narducy
Sociétés | Poste | Début | Fin |
---|---|---|---|
Colby Pharmaceutical Co.
![]() Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Président | 01/01/2006 | 01/01/2013 |
ABBOTT LABORATORIES | Directeur Technique/Scientifique/R&D | - | - |
Wesley Jessen VisionCare, Inc. | Directeur Technique/Scientifique/R&D | - | - |
CooperVision Pharmaceuticals, Inc. | Directeur Technique/Scientifique/R&D | 17/09/2009 | - |
Corporate Officer/Principal | - | 17/09/2009 | |
Oculex Pharmaceuticals, Inc.
![]() Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | President | - | - |
Centaur Pharmaceuticals, Inc. | Corporate Officer/Principal | - | - |
Formation de Kenneth W. Narducy
The Ohio State University | Doctorate Degree |
The University of Chicago | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 11 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
President | 2 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ABBOTT LABORATORIES | Health Technology |
Entreprise privées | 7 |
---|---|
Colby Pharmaceutical Co.
![]() Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Health Technology |
St. Charles Pharmaceuticals | |
Centaur Pharmaceuticals, Inc. | Health Technology |
Oculex Pharmaceuticals, Inc.
![]() Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Health Technology |
CooperVision Pharmaceuticals, Inc. | |
Wesley Jessen VisionCare, Inc. | Health Technology |
NeuroNascent, Inc.
![]() NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | Health Technology |
- Bourse
- Insiders
- Kenneth W. Narducy
- Expérience